India | Malawi | |
---|---|---|
N | 283 | 58 |
Caesarean delivery | 62/283 (21.9) | 0 (0.0) |
Birthweight (kg), mean (s.d.) | 2.96 (0.43) | 3.02 (0.45) |
Female | 152 (49.5) | 60 (50.4) |
Polio vaccine schedule | ||
Trivalent OPV | 51 (18.0) | – |
Mixed trivalent/bivalent OPVa | 56 (19.8) | – |
Bivalent OPVa | 84 (29.7) | 58 (100.0) |
IPVb | 92 (32.5) | – |
Exclusive breastfeeding up to 11 weeks of life | 243 (85.9) | 53 (91.4) |
Exposed to antibiotics up to 14 weeks of life | 204 (72.1) | 43 (74.1) |
HIV status | ||
Exposed | 0 (0.0) | 15 (25.9) |
Unexposed | 275 (97.2) | 41 (70.7) |
Unknown | 8 (2.8) | 0 (0.0) |
Neonatal rotavirus infectionc | 149/281d (53.0) | 6/47d (12.8) |
Seroconverted to ORV | 78/282d (27.7) | 10/56d (17.9) |
Shed ORV at week of life 7 (1 week after dose 1) | 74/281d (26.3) | 21/47d (44.7) |
RV-IgA at week of life 6 (before dose 1), GM (95% CI) | 7.3 (5.9–9.1)e | 3.4 (2.5–4.6) |
RV-IgA at week of life 14 (4 weeks after dose 2), GM (95% CI) | 18.9 (14.9–23.9) | 6.4 (4.0–10.2) |